The specific mechanisms include ... the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor (sintilimab) and PCSK9 inhibitor (tafolecimab) in the treatment of ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

Though currently experimental, this mechanism could complement existing PD-1 and PD-L1 checkpoint inhibitors and improve patient outcomes. Checkpoint inhibitors are one of many tools to fight cancer.

New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications ...

PD-1 and PD-L1 inhibitors are immunotherapies designed to block this mechanism, allowing the immune system to recognize and attack tumors. PD-1 is a receptor found on T-cells, while PD-L1 is its ...

"PD-1 inhibition has a 'yin and yang' nature: it activates anti-tumor immunity but at the same time impedes B-cell immunity. And this duality seems to stem from a conserved mechanism of immune ...

3, 4 The mechanism of the rescue of NSCLC patients ... We are excited to explore the potential of our PD-1 inhibitor, tislelizumab, in combination with ANKTIVA,” said John V.

Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune ... tumor responses achieved with PD-1/PD-L1 blockade alone.